Intervention Protocol

Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma

  1. Liat Vidal1,*,
  2. Ronit Gurion2,
  3. Anat Gafter-Gvili1,
  4. Pia Raanani2,
  5. Tadeusz Robak3,
  6. Ofer Shpilberg2

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 5 OCT 2011

DOI: 10.1002/14651858.CD009341


How to Cite

Vidal L, Gurion R, Gafter-Gvili A, Raanani P, Robak T, Shpilberg O. Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD009341. DOI: 10.1002/14651858.CD009341.

Author Information

  1. 1

    Beilinson Hospital, Rabin Medical Center, Department of Medicine E, Petah Tikva, Israel

  2. 2

    Beilinson Hospital, Rabin Medical Center, Institute of Hematology, Davidoff Center, Petah Tikva, Israel

  3. 3

    Medical University of Lodz and Copernicus Memorial Hospital, Department of Hematology, Lodz, Poland

*Liat Vidal, Department of Medicine E, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski Street, Petah Tikva, 49100, Israel. VidalL2@clalit.org.il. vidallit@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 5 OCT 2011

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effect of chlorambucil compared to other therapeutic regimens on overall survival, progression free survival, and response rates in patients with CLL/SLL requiring therapy. We will include patients receiving chlorambucil as first-line therapy and patients with relapsed or refractory CLL/SLL receiving salvage therapy with chlorambucil.